0.00Open0.04Pre Close0 Volume0 Open Interest1.00Strike Price0.00Turnover0.00%IV-74.06%PremiumDec 20, 2024Expiry Date3.01Intrinsic Value100Multiplier28DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma100.25Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Clene Stock Discussion
Dow Jones· just
Wed, Oct 2, 2024 at 7:21 AM EDT
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community.
LOS ANGELES, CA - (NewMediaWire) - October 2, 2024 - Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal functio...
Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS
Clene Inc. (Nasdaq: CLNN) has submitted new CNM-Au8 biomarker and clinical efficacy data to the FDA for ALS treatment. Key findings include:
1. CNM-Au8 NfL Responders showed significant improvements in survival, functional status, and combined function and survival.
2. Long-term CNM-Au8 treatmentdemonstrated substantial survival benefits compared to matched cont...
👀👀
plz do something about how ur system calculate RS value...
No comment yet